34
nanotimes
10-02 :: February 2010
Companies
Facts
funds from the American Recovery and Reinvestment Dyesol and Corus: 7. Milestone
Act by the U.S. Department of Energy to support
high-efficiency solid state lighting projects. Veeco
announced further its financial results for the fourth T
he partnership between Dyesol (ASX: DYE)
and Corus to develop and industrialise dye
quarter and full year ended December 31, 2009. solar cells (DSC) on coil steel has achieved the se-
John R. Peeler, Veeco’s CEO, commented, “Our venth milestone of the joint programme under the
fourth quarter revenue was $146 million, a record Welsh Assembly Government (WAG) contract. The
level for Veeco, increasing 33% from the fourth project, supported by the WAG with more than
quarter of 2008 and 48% sequentially. This strong £5 million (US$7,466 million), has now passed
revenue drove EBITA of $25.1 million, GAAP EPS of its seventh milestone and continues to be well
$0.50 per share, and non-GAAP EPS of $0.41 per ahead of schedule. At the Milestone 7 review held
share. Fourth quarter LED & Solar revenues were a recently with WAG in the joint PV Accelerator at
record $98 million, with MOCVD revenues more the Corus Shotton site, Dyesol and Corus showed
than doubling on a sequential basis. All three of our the processes used to produce modules already
businesses, LED & Solar, Data Storage, and Metro- manufactured on the pilot production line and de-
logy reported improved sequential gross margins, monstrated the long-term accelerated testing and
with overall Veeco margins increasing to 45%. Veeco outdoor weathering facilities that are now being
generated $37 million in cash from operations during used to evaluate the panels.
the fourth quarter. Veeco’s fourth quarter 2009
orders were $262 million, surpassing our prior record The Alpha Model programme, now in its third
of $226 million achieved in the third quarter by 16% month, has completed two production runs for
and nearly 200% higher than the fourth quarter of conformance testing on the roll-to-roll pilot line.
2008.” During this phase over the next few months the

http://www.veeco.com processes are being refined and new tooling and
automation are being introduced to enhance
T
he Westaim Corporation (TSX: WED; NUCRYST reproducibility and manufacturability of the roll-
Pharmaceuticals Corp., NASDAQ: NCST; TSX: to-roll facility. The product being manufactured
NCS) has completed the second and final tranche in each stage of the programme is then subjected
of its private placement with the sale of 3,255,000 to extensive testing at the in-house facilities to
subscription receipts at a purchase price of $0.50 establish priorities for the subsequent production
each for gross proceeds of $1,627,500 bringing the trials.
aggregate gross proceeds of this financing to $275

http://www.dyesol.com
million. The aggregate proceeds will be used to fund
the Company‘s previously announced acquisition of

http://www.coruscolors.com
JEVCO Insurance Company.

http://www.westaim.com
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69